Report overview
Celiac disease, also known as celiac sprue or gluten-sensitive enteropathy, is a genetic autoimmune disorder caused due to the body?s inability to process gluten that causes damage to the small intestine. Gluten, a protein found in wheat, barley, and rye, can damage the lining of the small intestine which makes it difficult for the body to absorb nutrients such as iron, fat, calcium, and folate. The immune system mistakes substances inside gluten to be a threat to the body and attacks them, in turn, causing damage to the bowel surface and hampering the body?s ability to absorb nutrition. Digestion problems, dermatitis herpetiformis, abdominal pain, weight loss, musculoskeletal problems, aphthous ulcers, iron deficiency, stunted growth, tingling sensation in the leg, and missed menstrual cycles are some of the symptoms of celiac disease. The disease can lead to various complications and health problems such as miscarriage or infertility, intestinal cancer, osteoporosis, seizures, gall bladder malfunction, neurological manifestation of the disease, stunted growth in children, and birth defects. Celiac disease can also lead to various autoimmune diseases such as lupus, thyroid disease, Sj?gren's syndrome, type 1 diabetes, and rheumatoid arthritis. It is difficult to diagnose celiac disease in the initial stages as its symptoms are similar to those of other diseases. Various sensitive and selective blood tests such as anti-tissue transglutaminase antibodies with or without IgA level and IgA anti-endomysial antibodies are used to screen the disease.
This report contains market size and forecasts of Celiac Drugs in global, including the following market information:
Global Celiac Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Celiac Drugs Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Celiac Drugs companies in 2021 (%)
The global Celiac Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
First Line Of Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Celiac Drugs include ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, Biotest, Bristol-Myers Squibb and Celgene, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Celiac Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Celiac Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Celiac Drugs Market Segment Percentages, by Type, 2021 (%)
First Line Of Treatment
Second Line Of Treatment
Global Celiac Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Celiac Drugs Market Segment Percentages, by Application, 2021 (%)
Men
Women
Children
Global Celiac Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Celiac Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Celiac Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Celiac Drugs revenues share in global market, 2021 (%)
Key companies Celiac Drugs sales in global market, 2017-2022 (Estimated), (K MT)
Key companies Celiac Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
ADMA Biologics
Amgen
Anthera Pharmaceuticals
Bayer
Biogen
BioLineRx
Biotest
Bristol-Myers Squibb
Celgene
Celimmune
F Hoffmann-La Roche
ImmunogenX
Immunomedics
ImmusanT
Innovate Biopharmaceuticals
Johnson & Johnson
Kedrion Biopharma
LFB Group
Merck
Novartis
